These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 946595)

  • 81. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine.
    Kataoka T; Sakurai Y
    Recent Results Cancer Res; 1980; 70():147-51. PubMed ID: 7355245
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)].
    Takenaka T; Kimura K
    Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2322-8. PubMed ID: 3831176
    [No Abstract]   [Full Text] [Related]  

  • 83. Effects of a new adenosine deaminase inhibitor, isocoformycin, on toxicity, antitumor activity and tissue distribution of formycin A and 9-beta-D-arabinofuranosyladenine.
    Hidaka T; Katayama K; Yamashita K; Yamashita T; Watanabe K; Shimazaki M; Ohno M; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1980 Mar; 33(3):303-9. PubMed ID: 7380742
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine.
    Bai L; Yamaguchi M; Tatsumi M; Kon K; Bräutigam M
    J Cancer Res Clin Oncol; 1998; 124(7):367-73. PubMed ID: 9719499
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids.
    Hong CI; Kirisits AJ; Nechaev A; Buchheit DJ; West CR
    J Med Chem; 1990 May; 33(5):1380-6. PubMed ID: 2329558
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Sequence-dependent antitumor effect of VP-16 and 1-beta-D-arabinofuranosylcytosine in L1210 ascites tumor.
    Ohkubo T; Higashigawa M; Kawasaki H; Kamiya H; Sakurai M; Kagawa Y; Kakito E; Sumida K; Ooi K
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1823-8. PubMed ID: 3220079
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Antiproliferative effects of 9-beta-d-arabinofuranosyladenine in a mammalian cell line devoid of adenosine deaminase activity.
    Drach JC; Sandberg JN; Shipman C
    J Dent Res; 1977 Mar; 56(3):275-88. PubMed ID: 192768
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A methodological approach to the prediction of anticancer drug effect in humans.
    Durkin WJ; Ghanta VK; Balch CM; Davis DW; Hiramoto RN
    Cancer Res; 1979 Feb; 39(2 Pt 1):402-7. PubMed ID: 761212
    [TBL] [Abstract][Full Text] [Related]  

  • 89. 1-beta-D-arabinofuranosylcytosine-phospholipid conjugates as prodrugs of Ara-C.
    Hong CI; An SH; Buchheit DJ; Nechaev A; Kirisits AJ; West CR; Ryu EK; MacCoss M
    Cancer Drug Deliv; 1984; 1(3):181-90. PubMed ID: 6544120
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pharmokinetics of 2'-deoxycoformycin in normal and L1210 leukemic mice.
    McConnell WR; Furner RL; Hill DL
    Drug Metab Dispos; 1979; 7(1):11-3. PubMed ID: 35319
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Antitumor characteristics of the conjugate of N4-(4-carboxybutyryl)-ara-C with ethylenediamine-introduced dextran and its resistance to cytidine deaminase.
    Onishi H; Pithayanukul P; Nagai T
    Drug Des Deliv; 1990 Oct; 6(4):273-80. PubMed ID: 1707277
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity.
    Cristalli G; Vittori S; Eleuteri A; Grifantini M; Volpini R; Lupidi G; Capolongo L; Pesenti E
    J Med Chem; 1991 Jul; 34(7):2226-30. PubMed ID: 2066996
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA.
    Spriggs D; Robbins G; Mitchell T; Kufe D
    Biochem Pharmacol; 1986 Jan; 35(2):247-52. PubMed ID: 3942598
    [TBL] [Abstract][Full Text] [Related]  

  • 94. N-trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies.
    Parker LM; Hirst M; Israel M
    Cancer Treat Rep; 1978 Jan; 62(1):119-27. PubMed ID: 272230
    [No Abstract]   [Full Text] [Related]  

  • 95. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
    Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
    Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Adenosine deaminase inhibition for immunosuppression.
    Chassin MM; Chirigos MA; Johns DG; Adamson RH
    N Engl J Med; 1977 May; 296(21):1232. PubMed ID: 854065
    [No Abstract]   [Full Text] [Related]  

  • 97. Analysis by high-pressure liquid chromatography of 9-beta-D-arabinofuranosyladenine 5'-triphosphate levels in murine leukemia cells.
    Rose LM; Brockman RW
    J Chromatogr; 1977 Mar; 133(2):335-43. PubMed ID: 557057
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [The mechanism of synergistic interaction between etoposide and cytarabine].
    Ooi K
    Yakugaku Zasshi; 2002 Jul; 122(7):471-80. PubMed ID: 12136643
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Biochemical and biophysical approaches to improving the anticancer effectiveness of Ara-adenine.
    Miles DL; Miles DW; Eyring H
    Med Hypotheses; 1982 Nov; 9(5):529-49. PubMed ID: 6296645
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.
    Kataoka T; Kobayashi T
    Ann N Y Acad Sci; 1978; 308():387-94. PubMed ID: 279298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.